The weight loss industry is experiencing a seismic shift driven by GLP-1 receptor agonists like semaglutide and tirzepatide. Demand for medically supervised weight management has skyrocketed, and entrepreneurs are racing to launch clinics that can serve this market. But the regulatory complexity of weight loss medicine, especially when delivered via telehealth, makes compliance a non-negotiable foundation for any sustainable business.
This guide covers the key compliance considerations for launching a weight loss clinic in 2026, from prescribing requirements to corporate structure.
GLP-1 Prescribing Requirements
GLP-1 receptor agonists are prescription medications that require appropriate clinical evaluation before prescribing. While these medications are not controlled substances, they carry specific prescribing considerations that your clinical protocols must address:
- Medical necessity documentation: Clinicians must document that the patient meets clinical criteria for the medication, typically including BMI thresholds and comorbidity assessments
- Contraindication screening: Proper screening for contraindications including personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, and pancreatitis
- Lab work requirements: Many clinical guidelines recommend baseline labs including A1C, thyroid function, lipid panel, and renal function before initiating GLP-1 therapy
- Ongoing monitoring: Regular follow-up visits to assess efficacy, side effects, and the need for dose adjustments
The FDA has issued warnings about the use of compounded semaglutide products. If your clinic plans to use compounded medications, understand that the regulatory landscape is evolving rapidly and additional compliance obligations may apply.
Telehealth Weight Loss: Regulatory Considerations
Delivering weight loss services via telehealth introduces additional compliance layers. The DEA's pandemic-era telehealth flexibilities for prescribing have been modified, and the rules for prescribing weight loss medications remotely depend on the specific medication and state law.
Standard Telehealth Prescribing
For non-controlled weight loss medications like GLP-1 agonists, standard telehealth prescribing rules apply. In most states, a synchronous audio-video visit is sufficient to establish a provider-patient relationship and prescribe. However, some states have specific requirements:
- Several states require an in-person visit before certain prescriptions can be issued via telehealth
- Some states restrict the prescribing of injectable medications via telehealth without an initial in-person evaluation
- Telehealth consent requirements vary by state and must be obtained before the first visit
Controlled Substances in Weight Management
If your weight loss clinic plans to prescribe controlled substances such as phentermine (Schedule IV), the regulatory requirements become significantly more complex. Key considerations include:
- DEA registration: Each prescribing clinician needs a DEA registration, and the clinic may need a separate registration
- In-person evaluation requirements: Federal rules now require an initial in-person or audio-video telehealth evaluation before prescribing controlled substances in most cases
- State-specific limitations: Many states impose additional restrictions on telehealth prescribing of controlled substances beyond federal requirements
- PDMP checks: Prescription Drug Monitoring Program queries are required in most states before prescribing controlled substances
NP and PA Supervision in Weight Loss Clinics
Most weight loss clinics rely heavily on nurse practitioners and physician assistants to deliver care at scale. The supervision requirements for these providers in the weight loss context depend on state law and the specific services being provided.
Critical supervision considerations include:
- Collaborative practice agreements: In states that require them, the CPA must specifically authorize the NP or PA to prescribe weight loss medications and manage obesity as a condition
- Collaborating physician specialty: The collaborating physician should ideally have expertise in obesity medicine, endocrinology, or internal medicine to provide meaningful clinical oversight
- Chart review frequency: Weight loss patients on GLP-1 medications may require more frequent chart review than general primary care patients due to the medication's side effect profile
- Scope alignment: Ensure that prescribing GLP-1 medications and managing weight loss falls within the NP's or PA's scope as defined by state law and their collaborative practice agreement
A common mistake is having a collaborating physician who is a dermatologist or psychiatrist overseeing NPs who are prescribing weight loss medications. The specialty mismatch creates a supervision arrangement that regulators may view as inadequate.
Corporate Structure: The MSO-PC Imperative
If your weight loss clinic is owned by non-physicians, whether entrepreneurs, private equity, or a technology company, you almost certainly need an MSO-PC structure. The corporate practice of medicine doctrine applies to weight loss medicine just as it does to any other medical practice.
Your structure should include:
- A professional corporation owned by a licensed physician that employs or contracts with your clinical team
- A management services organization that handles technology, marketing, billing, and operations
- A management services agreement that clearly delineates clinical versus administrative responsibilities
State-Specific Rules to Watch
Several states have implemented or are considering specific regulations around weight loss clinics and GLP-1 prescribing:
- California: Strict CPOM enforcement means your MSO-PC structure must be airtight, and the medical board has increased scrutiny of telehealth weight loss clinics
- Florida: Specific weight loss clinic licensing requirements that go beyond standard medical practice licensing
- Texas: Requires a specific weight loss clinic registration with the Texas Medical Board if certain medications are dispensed on-site
- New York: CPOM rules are aggressively enforced, and the state has specific telehealth regulations that affect how weight loss consultations can be conducted
Launching a weight loss clinic in 2026 requires navigating a complex intersection of prescribing rules, telehealth regulations, supervision requirements, and corporate structure laws. The companies that succeed will be those that build compliance into their foundation rather than treating it as an afterthought. The demand is there. The question is whether your compliance infrastructure can support sustainable growth.